Published in J Clin Oncol on February 21, 2012
Cholangiocarcinoma. Lancet (2014) 4.52
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest (2015) 1.92
STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypes. Sci Signal (2014) 1.79
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance. Clin Cancer Res (2013) 1.59
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget (2014) 1.11
Impact of interleukin-6 in hematological malignancies. Transfus Med Hemother (2013) 1.11
Trichomonosis, a common curable STI, and prostate carcinogenesis--a proposed molecular mechanism. PLoS Pathog (2012) 1.10
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol (2012) 1.03
The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT (2014) 1.03
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2015) 1.03
A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway. Oncotarget (2015) 0.99
Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden. Front Oncol (2014) 0.98
Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth. Proc Natl Acad Sci U S A (2013) 0.97
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer (2013) 0.97
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol (2015) 0.97
Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy. Sci Rep (2013) 0.96
MicroRNA-135b and Its Circuitry Networks as Potential Therapeutic Targets in Colon Cancer. Front Oncol (2013) 0.95
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Mol Cancer (2015) 0.94
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol (2014) 0.94
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
Apoptosis Induced by Tanshinone IIA and Cryptotanshinone Is Mediated by Distinct JAK/STAT3/5 and SHP1/2 Signaling in Chronic Myeloid Leukemia K562 Cells. Evid Based Complement Alternat Med (2013) 0.92
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer. Oncogene (2015) 0.91
Stress hormones promote growth of B16-F10 melanoma metastases: an interleukin 6- and glutathione-dependent mechanism. J Transl Med (2013) 0.91
Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer (2014) 0.91
Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation. PLoS Med (2014) 0.91
MiR-23a sensitizes nasopharyngeal carcinoma to irradiation by targeting IL-8/Stat3 pathway. Oncotarget (2015) 0.90
Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells. Mol Cancer Res (2013) 0.90
Salmonella modulation of host cell gene expression promotes its intracellular growth. PLoS Pathog (2013) 0.89
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth. Neoplasia (2015) 0.89
Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci (2014) 0.89
Personalized peptide vaccination: a novel immunotherapeutic approach for advanced cancer. Hum Vaccin Immunother (2012) 0.89
STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist (2014) 0.88
Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS (2013) 0.88
Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther (2014) 0.87
STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers (Basel) (2014) 0.87
Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells. J Biol Chem (2014) 0.87
Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility. J Biol Chem (2013) 0.87
Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Med (2015) 0.87
Acute inflammation induced by the biopsy of mouse mammary tumors promotes the development of metastasis. Breast Cancer Res Treat (2013) 0.87
Role of stat3 in skin carcinogenesis: insights gained from relevant mouse models. J Skin Cancer (2013) 0.86
Toxoplasmosis and Polygenic Disease Susceptibility Genes: Extensive Toxoplasma gondii Host/Pathogen Interactome Enrichment in Nine Psychiatric or Neurological Disorders. J Pathog (2013) 0.85
STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res (2015) 0.85
Increasing the range of drug targets: interacting peptides provide leads for the development of oncoprotein inhibitors. Bioengineered (2012) 0.85
Determinants of the extent and duration of STAT3 signaling. JAKSTAT (2012) 0.85
Transcription of the activating receptor NKG2D in natural killer cells is regulated by STAT3 tyrosine phosphorylation. Blood (2014) 0.85
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies. Leuk Lymphoma (2014) 0.84
Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia (2014) 0.83
Tetraspanin CD37 protects against the development of B cell lymphoma. J Clin Invest (2016) 0.81
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. Cancer Res Treat (2015) 0.81
Signal transducer and activator of transcription 3 signaling upregulates fascin via nuclear factor-κB in gastric cancer: Implications in cell invasion and migration. Oncol Lett (2014) 0.81
Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy. BMC Cancer (2014) 0.81
Obesity and IL-6 interact in modulating the response to endotoxemia in mice. Cytokine (2012) 0.81
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. World J Gastroenterol (2016) 0.81
LGR5 expression is controled by IKKα in basal cell carcinoma through activating STAT3 signaling pathway. Oncotarget (2016) 0.80
Sex, stem cells and tumors in the Drosophila ovary. Fly (Austin) (2012) 0.80
Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. Oncotarget (2016) 0.79
Salinomycin Promotes Anoikis and Decreases the CD44+/CD24- Stem-Like Population via Inhibition of STAT3 Activation in MDA-MB-231 Cells. PLoS One (2015) 0.79
STAT3 as a new autophagy regulator. JAKSTAT (2013) 0.79
Current status of immunotherapy for the treatment of biliary tract cancer. Hum Vaccin Immunother (2013) 0.79
Genetic Interactions of STAT3 and Anticancer Drug Development. Cancers (Basel) (2014) 0.79
Association of interleukin-6 genetic polymorphisms with risk of OSCC in Indian population. Meta Gene (2015) 0.79
Screening of the Human Kinome Identifies MSK1/2-CREB1 as an Essential Pathway Mediating Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication during Primary Infection. J Virol (2015) 0.78
Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. BMC Med Genomics (2014) 0.78
Granulin, a novel STAT3-interacting protein, enhances STAT3 transcriptional function and correlates with poorer prognosis in breast cancer. Genes Cancer (2015) 0.78
Inhibition of β-catenin and STAT3 with a curcumin analog suppresses gastric carcinogenesis in vivo. Gastric Cancer (2014) 0.78
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors. Oncoimmunology (2016) 0.78
Honokiol inhibits sphere formation and xenograft growth of oral cancer side population cells accompanied with JAK/STAT signaling pathway suppression and apoptosis induction. BMC Cancer (2016) 0.78
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget (2016) 0.77
Correlation analysis of STAT3 and VEGF expression and eosinophil infiltration in nasal polyps. Eur Arch Otorhinolaryngol (2014) 0.77
A sticky story for signal transducer and activator of transcription 3 in platelets. Circulation (2012) 0.77
Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat Commun (2016) 0.77
Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer. Int J Clin Exp Med (2014) 0.76
Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats. Biol Res (2015) 0.76
Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells. PLoS One (2012) 0.76
Impact of the N-Terminal Domain of STAT3 in STAT3-Dependent Transcriptional Activity. Mol Cell Biol (2015) 0.76
The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. Genome Biol (2016) 0.76
The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. PLoS One (2015) 0.76
RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. Oncotarget (2014) 0.76
Neuroprotective effect of interleukin-6 regulation of voltage-gated Na(+) channels of cortical neurons is time- and dose-dependent. Neural Regen Res (2015) 0.76
IL-1β induces IL-6 production and increases invasiveness and estrogen-independent growth in a TG2-dependent manner in human breast cancer cells. BMC Cancer (2016) 0.76
DC - SIGNR by influencing the lncRNA HNRNPKP2 upregulates the expression of CXCR4 in gastric cancer liver metastasis. Mol Cancer (2017) 0.76
Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines (2017) 0.75
MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma. PLoS One (2016) 0.75
Candidate genes on murine chromosome 8 are associated with susceptibility to Staphylococcus aureus infection in mice and are involved with Staphylococcus aureus septicemia in humans. PLoS One (2017) 0.75
At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol (2016) 0.75
Interleukin-6 from Ovarian Mesenchymal Stem Cells Promotes Proliferation, Sphere and Colony Formation and Tumorigenesis of an Ovarian Cancer Cell Line SKOV3. J Cancer (2016) 0.75
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematol (2017) 0.75
Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy. Invest Ophthalmol Vis Sci (2017) 0.75
Anti-interleukin-6 therapy through application of a monogenic protein inhibitor via gene delivery. Sci Rep (2015) 0.75
JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition. JAKSTAT (2013) 0.75
Effect of Th1/Th2 cytokine administration on proinflammatory SKOV-3 cell activation. Arch Med Sci (2015) 0.75
Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro. PLoS One (2016) 0.75
Circulating miRNAs as new activators of the JAK-STAT3 pathway. JAKSTAT (2013) 0.75
Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma (2015) 0.75
In vivo treatment of rat arterial adventitia with interleukin‑1β induces intimal proliferation via the JAK2/STAT3 signaling pathway. Mol Med Rep (2016) 0.75
Investigation of JAKs/STAT-3 in lipopolysaccharide-induced intestinal epithelial cells. Clin Exp Immunol (2016) 0.75
IL-17 and Th17 Cells. Annu Rev Immunol (2009) 23.02
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
STATs and gene regulation. Science (1997) 16.55
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol (2002) 15.33
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
STAT3 mutations in the hyper-IgE syndrome. N Engl J Med (2007) 8.99
STATs in oncogenesis. Oncogene (2000) 8.60
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell (2010) 8.04
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 7.90
Transcription factors as targets for cancer therapy. Nat Rev Cancer (2002) 7.27
Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature (2007) 7.07
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med (2005) 6.45
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science (1995) 6.28
gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell (2009) 6.26
Th17 and regulatory T cells in mediating and restraining inflammation. Cell (2010) 5.89
Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol (2003) 5.77
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science (2005) 5.31
JAK-STAT signaling: from interferons to cytokines. J Biol Chem (2007) 5.28
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol (2009) 4.76
Specific inhibition of Stat3 signal transduction by PIAS3. Science (1997) 4.74
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell (2009) 4.56
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science (1997) 4.37
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
Serine phosphorylation of STATs. Oncogene (2000) 4.21
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res (2010) 4.10
Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol (2006) 4.10
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (2009) 3.89
The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol (2004) 3.76
SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet (2001) 3.76
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest (2004) 3.70
The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol (2005) 3.65
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med (2011) 3.63
Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol (2002) 3.57
Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev (2007) 3.57
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell (2011) 3.47
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood (2010) 3.41
Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity (2011) 3.40
Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity (2011) 3.38
Myeloproliferative disorders. Blood (2008) 3.37
Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell (2009) 3.29
Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann N Y Acad Sci (2009) 3.27
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol (2003) 3.04
Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell (2008) 2.98
Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 2.83
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol (2005) 2.59
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem (1996) 2.47
Th17 cells: a new fate for differentiating helper T cells. Immunol Res (2008) 2.45
Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell (2010) 2.43
B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med (2010) 2.42
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med (2010) 2.41
Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A (2003) 2.35
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res (2011) 2.35
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res (2004) 2.24
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol (2006) 2.21
Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res (2005) 2.20
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology (2006) 2.13
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res (2011) 2.11
Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev (2006) 2.10
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med (2005) 2.06
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung. Cancer Res (2007) 2.04
Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer (2010) 2.04
STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling. J Virol (2003) 1.95
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol (2010) 1.94
The unholy trinity: inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell (2011) 1.92
Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol (2008) 1.85
Autoregulation of the Stat3 gene through cooperation with a cAMP-responsive element-binding protein. J Biol Chem (1998) 1.83
Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology (2010) 1.82
STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci U S A (2005) 1.80
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene (2002) 6.17
Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res (2006) 1.80
Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res (2006) 1.69
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol (2007) 1.41
Stat3 is required for the development of skin cancer. J Clin Invest (2004) 1.26
Th2 differentiation is necessary for soft tissue fibrosis and lymphatic dysfunction resulting from lymphedema. FASEB J (2012) 1.25
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res (2010) 1.17
Targeting the tumor microenvironment: JAK-STAT3 signaling. JAKSTAT (2013) 1.14
Environment, inflammation, and cancer. Curr Opin Genet Dev (2010) 1.06
Stat3 mediates expression of autotaxin in breast cancer. PLoS One (2011) 1.03
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Clin Cancer Res (2008) 1.03
Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res (2013) 0.91
STATe-of-the-art approach: using oligonucleotide decoys to target the "undruggable". Cancer Discov (2012) 0.79
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clin Cancer Res (2007) 0.78
A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. J Clin Invest (2017) 0.75
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2016) 0.75